Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-engineered dendritic cell vaccine (TetraMix)
- Development stage
- Preclinical
- Lead developer
- etherna
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous, Subcutaneous
01
Overview
mRNA-engineered dendritic cell vaccine (TetraMix) is an autologous, personalized, monocyte-derived dendritic cell (moDC) cancer vaccine. The vaccine is engineered ex vivo by electroporating patient-derived moDCs with patient-specific tumor neoantigen mRNA along with TetraMix, a novel four-component mRNA-based adjuvant. TetraMix consists of four mRNA molecules encoding constitutively active toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), interferon-gamma (IFN-gamma), and a decoy receptor for interleukin-10 (dIL10Ralpha). This combination of adjuvant mRNAs redirects the dendritic cells into an antiviral-like transcriptional program, enhancing their maturation, increasing interleukin-12 (IL-12) production, and promoting the activation of tumor-specific cytotoxic CD8+ T cells. Originally developed by the Vrije Universiteit Brussel (VUB) and licensed to etherna (formerly eTheRNA immunotherapies), the vaccine was also positioned for clinical development in colorectal cancer by the Persomed consortium, though clinical trials were halted due to funding constraints.
- Other names
- TetraMixTetraMix-DCTetraMix-engineered dendritic cell vaccineTetraMixDCs
Beyond the preview
Go deeper on mRNA-engineered dendritic cell vaccine (TetraMix).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-engineered dendritic cell vaccine (TetraMix).